290 related articles for article (PubMed ID: 22546763)
1. In vitro activity of tigecycline against Acinetobacter baumannii isolates from a teaching hospital in Malaysia.
Dhabaan GN; AbuBakar S; Shorman MA; Hassan H
J Chemother; 2012 Apr; 24(2):87-92. PubMed ID: 22546763
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.
Liu JW; Wang LS; Cheng YJ; Hsu GJ; Lu PL; Liu YC; Chen CM; Lee CM; Sun W; Jang TN; Chiang PC; Chuang YC; Lin HC; Shi ZY; Kung HC; Huang CH; Tsao SM; Lu CT; Liao CH; Hsueh PR
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S188-91. PubMed ID: 19013353
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of tigecycline against clinical isolates of multidrug-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand.
Tiengrim S; Tribuddharat C; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S102-5. PubMed ID: 17718251
[TBL] [Abstract][Full Text] [Related]
4. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.
Navon-Venezia S; Leavitt A; Carmeli Y
J Antimicrob Chemother; 2007 Apr; 59(4):772-4. PubMed ID: 17353223
[TBL] [Abstract][Full Text] [Related]
5. Unexpected tigecycline resistance among Acinetobacter baumannii Isolates: high minor error rate by Etest.
Kulah C; Celebi G; Aktas E; Mengeloglu Z; Comert F; Ankarali H
J Chemother; 2009 Aug; 21(4):390-5. PubMed ID: 19622456
[TBL] [Abstract][Full Text] [Related]
6. [In vitro tigecycline and carbapenem susceptibilities of clinical Acinetobacter baumannii isolates].
Nayman Alpat S; Aybey AD; Akşit F; Ozgüneş I; Kiremitçi A; Usluer G
Mikrobiyol Bul; 2010 Oct; 44(4):641-5. PubMed ID: 21063976
[TBL] [Abstract][Full Text] [Related]
7. Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals.
Al-Sweih NA; Al-Hubail MA; Rotimi VO
J Chemother; 2011 Feb; 23(1):13-6. PubMed ID: 21482488
[TBL] [Abstract][Full Text] [Related]
8. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.
Morfin-Otero R; Dowzicky MJ
Clin Ther; 2012 Jan; 34(1):101-12. PubMed ID: 22177546
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Resistance, Clonal Expansion, and Increasing Prevalence of Acinetobacter baumannii Strains Displaying Elevated Tigecycline MIC Values in Latin America.
Costello SE; Gales AC; Morfin-Otero R; Jones RN; Castanheira M
Microb Drug Resist; 2016 Jun; 22(4):253-8. PubMed ID: 26716768
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates.
Ricciardi R; Ricciardi AM; Danzi G
Infez Med; 2009 Dec; 17(4):236-9. PubMed ID: 20046104
[TBL] [Abstract][Full Text] [Related]
11. Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii clinical isolates, including multidrug-resistant isolates.
Piewngam P; Kiratisin P
Int J Antimicrob Agents; 2014 Nov; 44(5):396-401. PubMed ID: 25442358
[TBL] [Abstract][Full Text] [Related]
12. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.
Ni W; Cui J; Liang B; Cai Y; Bai N; Cai X; Wang R
J Antibiot (Tokyo); 2013 Dec; 66(12):705-8. PubMed ID: 23981963
[TBL] [Abstract][Full Text] [Related]
13. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods.
Liao CH; Kung HC; Hsu GJ; Lu PL; Liu YC; Chen CM; Lee CM; Sun W; Jang TN; Chiang PC; Cheng YJ; Lin HC; Shi ZY; Wang LS; Chuang YC; Tsao SM; Lu CT; Liu JW; Huang CH; Hsueh PR
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S192-6. PubMed ID: 19013354
[TBL] [Abstract][Full Text] [Related]
14. Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit.
Jamal W; Salama M; Dehrab N; Al Hashem G; Shahin M; Rotimi VO
J Hosp Infect; 2009 Jul; 72(3):234-42. PubMed ID: 19493588
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
Cai X; Yang Z; Dai J; Chen K; Zhang L; Ni W; Wei C; Cui J
Int J Antimicrob Agents; 2017 May; 49(5):609-616. PubMed ID: 28315729
[TBL] [Abstract][Full Text] [Related]
16. Rapid development of Acinetobacter baumannii resistance to tigecycline.
Reid GE; Grim SA; Aldeza CA; Janda WM; Clark NM
Pharmacotherapy; 2007 Aug; 27(8):1198-201. PubMed ID: 17655518
[TBL] [Abstract][Full Text] [Related]
17. Are E-test and Vitek2 good choices for tigecycline susceptibility testing when comparing broth microdilution for MDR and XDR Acinetobacter baumannii?
Grandesso S; Sapino B; Amici G; Mazzucato S; Solinas M; Gion M
New Microbiol; 2014 Oct; 37(4):503-8. PubMed ID: 25387287
[TBL] [Abstract][Full Text] [Related]
18. EVALUATION OF IN VITRO TIGECYCLINE ACTIVITY AGAINST MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII CLINICAL ISOLATES FROM POLAND.
Paluchowska P; Nowak P; Skalkowska M; Bjdak A
Acta Pol Pharm; 2017 May; 74(3):793-800. PubMed ID: 29513948
[TBL] [Abstract][Full Text] [Related]
19. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period.
Spiliopoulou A; Jelastopulu E; Vamvakopoulou S; Bartzavali C; Kolonitsiou F; Anastassiou ED; Christofidou M
J Chemother; 2015 Oct; 27(5):266-70. PubMed ID: 24827985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
